CompletedPhase 3

Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy

Germany62 participantsStarted 2022-12-02

Plain-language summary

The purpose of this study was to investigate the efficacy and safety of secukinumab subcutaneously (s.c.) compared to placebo in adult patients with moderate to severe rotator cuff tendinopathy and failure to conventional therapy.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. WORC score was ≤ 40 at Baseline.
✓. NRS pain score was ≥ 5 at Baseline and for at least 3 days of the 7 days prior to Baseline.
✓. Nocturnal pain occurred at least 4 out of the 7 days in the week prior to Baseline.

What they're measuring

Change From Baseline in the Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Percentage Score at Week 24

Timeframe: Baseline, Week 24

Trial details

NCT IDNCT05569174

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-12-18

Results submitted2025-11-14

View on ClinicalTrials.gov More Tendinopathy trials